[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594573":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":24,"interventions":31,"overallOfficials":35,"centralContacts":44,"locations":52,"responsibleParty":71,"collaborators":73,"id":76,"slug":17,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":17,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":17,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":17,"overallStatus":55,"whyStopped":17,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Grit Biotechnology","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence and severity of adversed events","To characterize the safety profile of GT719 in patients with recurrent\u002Frefractory antibody-mediated neurological immune diseases as measured by the incidence and severity of adverse events","24 months",[14],{"measure":15,"description":16,"timeFrame":12},"Pharmacokinetics of GT719 cells","Survival time of GT719 cells after infusion of GT719 Injection",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NA","SINGLE_GROUP","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE",[25],{"label":26,"type":27,"description":28,"interventionNames":29},"GT719 Injection treatment group","EXPERIMENTAL","GT719 Injection",[30],"Biological: GT719 Injection",[32],{"type":33,"name":28,"description":28,"armGroupLabels":34,"otherNames":17},"BIOLOGICAL",[26],[36,40,42],{"name":37,"affiliation":38,"role":39},"Wei Wang","Tongji Hospital","PRINCIPAL_INVESTIGATOR",{"name":41,"affiliation":38,"role":39},"Daishi Tian",{"name":43,"affiliation":38,"role":39},"Chuan Qin",[45,49],{"name":41,"role":46,"phone":47,"phoneExt":17,"email":48},"CONTACT","+8613607178809","tiands@tjh.tjmu.edu.cn",{"name":37,"role":46,"phone":50,"phoneExt":17,"email":51},"+86-27-83662640","wwang@tjh.tjmu.edu.cn",[53],{"facility":54,"status":55,"city":56,"state":57,"zip":17,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology","RECRUITING","Wuhan","Hubei","China","CN",{"type":61,"coordinates":62},"Point",[63,64],114.26667,30.58333,{"lat":64,"lon":63},[67,68,69,70],{"name":41,"role":46,"phone":47,"phoneExt":17,"email":48},{"name":37,"role":39,"phone":17,"phoneExt":17,"email":17},{"name":41,"role":39,"phone":17,"phoneExt":17,"email":17},{"name":43,"role":39,"phone":17,"phoneExt":17,"email":17},{"type":72,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR",[74],{"name":38,"class":75},"OTHER","100594573",false,"NCT07021209","GT719 Injection for Recurrent\u002FRefractory Antibody-mediated Neurological Immune Diseases","A Single-arm, Open-label, Phase I Clinical Study of GT719 Injection for Recurrent\u002FRefractory Antibody-mediated Neurological Immune Diseases","Inclusion Criteria:\n\n* Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.\n* Expected survival period\\>12 weeks.\n* Any previous systemic treatment must have undergone at least 4 weeks or 5 half lives (whichever is shorter) by the time the participant plans to receive the study treatment.\n\nExclusion Criteria:\n\n* History of organ transplantation, splenectomy, and allogeneic or autologous stem cell transplantation.\n* History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy.\n* Received systemic corticosteroids at a dose of ≥10 mg\u002Fday prednisone equivalent within 7 days prior to GT719 infusion, except for inhaled corticosteroids.","ALL","18 Years","75 Years",{"count":86,"type":87},30,"ESTIMATED","INTERVENTIONAL",[90],"PHASE1","This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent\u002Frefractory antibody-mediated neurological immune diseases.",[93],"Neurological Autoimmune Diseases","2025-09-08",{"date":96,"type":97},"2025-09-15","ACTUAL",{"date":99,"type":97},"2025-01-14",{"date":101,"type":87},"2028-01-13",{"name":5,"class":6},1]